**Technology Advisory Committee B Interests Register**

**Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1498]**

**Publication Date: 23/06/2021**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Dr Nicholas Latimer | TA Committee A Member  | Direct - financial | Received payment by Merck Serono to present methods for modelling treatment sequences at ISPOR Webinar. The presentation was unrelated to any specific drug or disease area. | NA | 10/03/2021 | NA | It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.  |
| Dr Nicholas Latimer | TA Committee A Member  | Direct non-financial interest | Current data sharing agreement with Amgen, manufacturer of a comparator drug. This agreement involves conducting methodological research analysing data from old studies of panitumumab in colorectal cancer. No payment is received by Dr Latimer or his institution. | NA | 10/03/2021 | NA | It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.  |
| Professor Mark Saunders | Clinical Expert  | Direct - financial | In the last 3 years, Professor Saunders was paid to chair meetings and/or lecture by Servier, Merck Serono and Amgen. | NA | 19/08/2020 | NA | It was agreed that this declaration would not prevent Professor Saunders from providing expert advice to the committee. |
| Professor Mark Saunders | Clinical Expert  | Non-financial professional and personal interests | Professor Saunders is the Chair of Bowel Cancer UK’s Medical Advisory Board. | NA | 19/08/2020 | NA | It was agreed that this declaration would not prevent Professor Saunders from providing expert advice to the committee. |
| Dr Kai-Keen Shui | Clinical Expert  | Indirect interests | Chief Investigator for:1) KEYNOTE 177 trial, April 2016 - 2) KEYNOTE 859 and KEYNOTE 811 (pembrolizumab metastatic gastric trials)3) upcoming MSD investigator led/UCL sponsored trial - NEOPRISM-CRC - of neo-adjuvant pembrolizumab for operable MMR-d/MSI-H colorectal cancer. In all instances, the trials are ongoing and all monies go to UCLH or UCL.Co-author of ASCO 2020 Abstract and two papers relating to KEYNOTE 177. | NA | 15/02/2020 | NA | It was agreed that these declarations would not prevent Dr Shui from providing expert advice to the committee. |
| Dr Kai-Keen Shui | Clinical Expert  | Indirect interests | Dr Shui’s institution received research funding from BMS, Gilead Sciences, Merck KGaA, MSD and Roche  | NA | 12/01/2021 | NA | It was agreed that these declarations would not prevent Dr Shui from providing expert advice to the committee. |
| Dr Kai-Keen Shui | Clinical Expert  | Direct financial  | Travel, accommodations and expenses from Innovent Biologics, Merck KGaA and Roche | NA | 12/01/2021 | NA | It was agreed that these declarations would not prevent Dr Shui from providing expert advice to the committee. |
| Dr Kai-Keen Shui | Clinical Expert  | Direct - financial | Received consultancy fees and partook in paid advisory boards for MSD and Roche. Dr Shui is on the Council and paid advisory board for Mirati Therapeutics. Dr Shui has also received honoraria for educational talks to oncologists about managing CRC and UGI cancers from: MSD, Innovent Biologics, Merck KGaA and Daiiichi-Sankyo, BMS, Guardant Health and Roche. | NA | 24/03/2021 | NA | It was agreed that these declarations would not prevent Dr Shui from providing expert advice to the committee. |